Increased Thrombotic Risk in COVID-19: Evidence and Controversy

Vita, Antonio De; Franceschi, Francesco; Covino, Marcello

doi:10.3390/jcm12134441

Cited by 2 publications

(1 citation statement)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have investigated the role of various biomarkers in the evaluation of mortality risk in terms of the escalation of respiratory support [ 32 ] and complication rate [ 33 ]. Careful evaluation of laboratory parameters may be helpful for estimating the severity of infection and patient prognosis [ 34 , 35 ].…”

Section: Discussionmentioning

confidence: 99%

Assessment of COVID-19 risk factors of early and long-term mortality with prediction models of clinical and laboratory variables

Lipski,

Radziemski,

Wasiliew

et al. 2024

BMC Infect Dis

View full text Add to dashboard Cite

Background Coronavirus disease (COVID-19) may lead to serious complications and increased mortality. The outcomes of patients who survive the early disease period are burdened with persistent long-term symptoms and increased long-term morbidity and mortality. The aim of our study was to determine which baseline parameters may provide the best prediction of early and long-term outcomes. Methods The study group comprised 141 patients hospitalized for COVID-19. Demographic data, clinical data and laboratory parameters were collected. The main study endpoints were defined as in-hospital mortality and 1-year mortality. The associations between the baseline data and the study endpoints were evaluated. Prediction models were created. Results The in-hospital mortality rate was 20.5% (n = 29). Compared with survivors, nonsurvivors were significantly older (p = 0.001) and presented comorbidities, including diabetes (0.027) and atrial fibrillation (p = 0.006). Assessment of baseline laboratory markers and time to early death revealed negative correlations between time to early death and higher IL-6 levels (p = 0.032; Spearman rho − 0.398) and lower lymphocyte counts (p = 0.018; Pearson r -0.438). The one-year mortality rate was 35.5% (n = 50). The 1-year nonsurvivor subgroup was older (p < 0.001) and had more patients with arterial hypertension (p = 0.009), diabetes (p = 0.023), atrial fibrillation (p = 0.046) and active malignancy (p = 0.024) than did the survivor subgroup. The model composed of diabetes and atrial fibrillation and IL-6 with lymphocyte count revealed the highest value for 1-year mortality risk prediction. Conclusions Diabetes and atrial fibrillation, as clinical factors, and LDH, IL-6 and lymphocyte count, as laboratory determinants, are the best predictors of COVID-19 mortality risk.

show abstract

Section: Discussionmentioning

confidence: 99%

Assessment of COVID-19 risk factors of early and long-term mortality with prediction models of clinical and laboratory variables

Lipski,

Radziemski,

Wasiliew

et al. 2024

BMC Infect Dis

View full text Add to dashboard Cite

show abstract

Роль Циркулирующих Биомаркеров У Пациентов, Перенесших COVID-19

Осипова,

Шепель,

Каруцкая

et al. 2023

АПМ

View full text Add to dashboard Cite

Новая коронавирусная инфекция внесла весомые коррективы в состояние пациентов, уже страдающих сердечно-сосудистыми заболеваниями. Похожие механизмы развития фиброза у пациентов с тяжелой формой COVID-19 и сердечной недостаточностью заставили обратить внимания на биомаркеры воспаления. Тяжелый цитокиновый шторм, характерный для COVID-19, имеет решающее значение для понимания исхода заболевания. При тяжелом течении COVID-19 отмечены высокие уровни интерлейкина-2, интерлейкина-6, интерлейкина-10, моноцитарного хемотаксического белка-1 (MCP-1) и фактора некроза опухоли-α (TNF-α), в отличие от пациентов с легкой и умеренной формой заболевания. Повышение уровня MCP-1 при тяжелом течении COVID-19 позволяет предположить, что его секреция может играть одну из ключевых ролей в реактивном воспалительном процессе, связанном с COVID-19. Установлено, что ИЛ-10 и MCP-1 являются предикторами тяжести заболевания COVID-19 и риска смерти таких пациентов. Матриксные металлопротеиназы (ММП) также оказываются вовлечены в развитие патологии легких и могут выступать в качестве раннего индикатора дыхательной недостаточности у пациентов с COVID-19. В данном обзоре рассмотрены биомаркеры воспаления, такие как ММП, тканевой ингибитор матриксной металлопротеиназы-1, интерлейкины, MCP-1, на предмет их возможности служить объективными маркерами ранней диагностики и прогноза развития сердечно-сосудистых осложнений у пациентов, перенесших COVID-19.

show abstract

Increased Thrombotic Risk in COVID-19: Evidence and Controversy

Abstract: The pandemic of respiratory disease caused by the novel coronavirus named SARS-CoV-2, which emerged at the end of 2019, is still ongoing [...]

Cited by 2 publications

References 56 publications

Assessment of COVID-19 risk factors of early and long-term mortality with prediction models of clinical and laboratory variables

Assessment of COVID-19 risk factors of early and long-term mortality with prediction models of clinical and laboratory variables

Роль Циркулирующих Биомаркеров У Пациентов, Перенесших COVID-19

Contact Info

Product

Resources

About